|4/AOct 2, 3:37 PM ET

Abraham Todd 4/A

4/A · ENDOLOGIX INC /DE/ · Filed Oct 2, 2012

Insider Transaction Report

Form 4/AAmended
Period: 2012-09-09
Abraham Todd
VP of Operations
Transactions
  • Award

    Common Stock

    2012-09-09$12.62/sh+28,944$365,27359,138 total
Footnotes (5)
  • [F1]25% vesting to occur upon the achievement of Nellix device revenue target for a month.
  • [F2]25% vesting to occur upon U.S. regulatory approval of Nellix device.
  • [F3]25% vesting to occur upon U.S. regulatory approval of Ventana device.
  • [F4]25% vesting to occur upon U.S.regulatory approval of a second-generation AFX device.
  • [F5]100% cliff vesting to occur 9/9/2016 in the event milestones are not achieved.

Documents

1 file
  • 4
    doc4a.xml

    FORM 4/A SUBMISSION